Abbvie Will BEAT Q316 of $1.20 ....Comes in At $1.22

Discussion in 'AbbVie' started by anonymous, Oct 25, 2016 at 1:53 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Driven by Humira and Imbruvica and a weaker Viekira which lags because of the liver warning
     

  2. anonymous

    anonymous Guest

    AbbVie will get label expansion of Imbruvica to include treatment of marginal zone lymphoma MZL, a slow-growing form of non-Hodgkins lymphoma. AbbVie expects Imbruvica peak sales of OVER $7 BILLION and revenues of about $5 BILLION in 2020. Ricky is working on expanding Imbruvica's label to include solid tumors and autoimmune diseases. There's also a registrational study for graft-versus-host disease which is ALREADY underway, The data is expected in December or January. Don't believe the Abbvie haters on here
     
  3. anonymous

    anonymous Guest

    Looking long term to Humira loss .....the clueless sheep on here who are a disaster in terms of knowledge about Humira I'll correct the mis information Amgen patent litigation will go on for 42 months..... FDA ruling means NOTHING. By 2020 Imbruvica will be pulling in $7 BILLiON a year and StemCentrx deal with Rova- T (DLL3) will be pulling in $5 BILLION by 2020....There alone is $12 Billion offsetting Humira loss. New indications for raise this even higher.......If the street doubted this ABBV would be @ $40 ...They DONT and it sits in Low $60 with $72 high end predicted
     
  4. anonymous

    anonymous Guest

    Now it's the liver warning. Always something.
     
  5. anonymous

    anonymous Guest

    Can AbbVie (ABBV) Sustain Earnings Beat Trend in Q3?
    October 24, 2016, 04:27:00 PM EDT By Zacks Equity Research, Zacks.com

    ANSWER IS YES YES YES !!!!!!!!!!!!!!!!


    ABBV to beat expectations when it reports third-quarter earnings results on Oct 28 before market open. AbbVie had delivered a positive earnings surprise of 5.00% in the second quarter.

    AbbVie's performance has been pretty impressive, with consistent positive surprises. The average earnings beat over the last four quarters is 3.32%.



    ABBVIE INC Price and EPS Surprise



    [​IMG]

    ABBVIE INC Price and EPS Surprise | ABBVIE INC Quote



    Let's see how things are shaping up for the company this quarter:

    Factors at Play

    At the second-quarter conference call, management had said that it expects third-quarter earnings in the range of $1.18 to $1.20 per share. Revenues were guided to see high single-digit operational growth, excluding a modest negative foreign exchange impact.

    Key drug Humira should remain the main growth driver in the third quarter. Growing awareness, strong underlying demand, favorable clinical data, additional indications and market share gains should help the product to continue contributing significantly to the top line.

    However, a factor to be considered for international Humira sales is the impact of Remicade and Enbrel biosimilars.

    Another area of focus is the performance of Imbruvica which was added to AbbVie's portfolio following its May 2015 acquisition of Pharmacyclics. Imbruvica has multi-billion dollar potential that the company is exploring to expand Imbruvica's label into solid tumors and autoimmune diseases.

    The drug recorded strong sales and share gains in the second quarter, a trend we expect to continue.

    AbbVie is positioning Imbruvica as a "pipeline in a molecule" -- a treatment that is currently used in a wide range of studies. Imbruvica is partnered with Johnson & Johnson JNJ , which recorded third-quarter Imbruvica sales of $349 million.

    Other drugs like Duopa and Creon should also do well in the quarter to be reported.

    However, Abbvie's Hepatitis C virus (HCV) treatment, Viekira, will continue to be impacted by the addition of liver injury warnings to the labels of AbbVie's HCV treatments as well as new competition in the market.

    What Our Model Indicates

    Our proven model shows that AbbVie is likely to beat on earnings because it has the right combination of the two key ingredients.

    Positive Zacks ESP: Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +0.83%. This is a meaningful indicator of a likely positive earnings surprise.

    Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks of #1, #2 and #3 have a significantly higher chance of beating earnings. The Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement.

    The combination of ABbVie's Zacks Rank #3 and +0.83% ESP makes us confident in looking for an earnings beat in the upcoming release.

    Other Stocks to Consider

    Some other stocks in the large-cap healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are:

    Amgen Inc. AMGN , which is scheduled to report results on Oct 27. The company has an Earnings ESP of +1.08% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

    Novartis AG NVS with an Earnings ESP of +2.54% and a Zacks Rank #3. The company is scheduled to release results on Oct 25.



    Read more: http://www.nasdaq.com/article/can-abbvie-abbv-sustain-earnings-beat-trend-in-q3-cm697501#ixzz4O6wKGkDL
     
  6. anonymous

    anonymous Guest

    Also the recent approval in first-line chronic lymphocytic leukemia (CLL), Imbruvica is being transitioned into this setting from the relapsed/refractory setting. There's major uptake in 1L CLL over the next few years, given the broad label achieved with the RESONATE-2 study, helped by further additional studies with other combinations This will Possibly add another $2-$3 Billion to Imbruvica .....TRINITY study in 3L DLL3 SCLC is on track to read out in q2 2017 and Ricky expects an accelerated approval decision based on response rates and duration of response data.
    If Amgen is stupid enough to try at-risk launch, with Abbvies security of broad patent estate on Humira significant damages could be put against them if later found to infringe on Humira's IP.....I think I penalty is 300% (3X) amount of damages incurred. PLUS Humira will STILL have 15-30% of market share into 2030 and beyond
     
  7. anonymous

    anonymous Guest

    ZACKS SUCKS - is wrong more times than not
     
  8. anonymous

    anonymous Guest

    I get calls from Zacks all the time trying to sell me 'hot' stocks.... what a bunch of MORONS
     
  9. anonymous

    anonymous Guest

    That was Mr Zacks from welfare office calling, Your food stamps were discontinued .
     
  10. anonymous

    anonymous Guest

    Abbv Beats Street Read Em Weep Trolls
    - Reports Third-Quarter Diluted EPS of $0.97 on a GAAP Basis; Adjusted Diluted EPS of $1.21, Reflecting Growth of 7.1 Percent Over Third-Quarter 2015
    - Delivers Third-Quarter Net Revenues of $6.43 Billion on a GAAP Basis; Adjusted Net Revenues Grew 8.0 Percent on an Operational Basis
    - Revenue Growth Reflects 11.3 Percent HUMIRA Global Reported Sales Growth; 12.1 Percent Growth on an Operational Basis
    - Third-Quarter Global IMBRUVICA Net Revenue was $501 Million
    - Reports Operating Margin of 36.7 Percent on a GAAP Basis; 42.8 Percent on an Adjusted Basis
    - Raises 2016 GAAP Diluted EPS Guidance Range to $3.74 to $3.76 and Adjusted EPS Guidance Range to $4.80 to $4.82, Representing Growth of 12.1 Percent at the Midpoint
    - Announces 2017 Dividend Increase of 12 Percent, Beginning with Dividend Payable in February 2017
     
  11. anonymous

    anonymous Guest

    Ricky's a Genuis
     
  12. anonymous

    anonymous Guest

    Financial engineering to boost EPS doesn't make up for revenue miss..... combined with Humira uncertainty.....

    Currently down -9%
     
  13. anonymous

    anonymous Guest

    a little bounce.... now down only -7.5%
     
  14. anonymous

    anonymous Guest

    AbbVie Common Stock
    NYSE: ABBV - Nov 7, 11:17 AM EST
    57.82 USD1.79 (3.19%)
     
  15. anonymous

    anonymous Guest

    AbbVie Common Stock
    NYSE: ABBV - Nov 7, 5:13 PM EST
    $58.91 USDUP $2.87 (5.12%)
    After-hours: $59.45UP (0.92%)
     
  16. anonymous

    anonymous Guest

    awesome, wasn't Abbvie @ $71.23 only 17 months ago?
     
  17. anonymous

    anonymous Guest

    So is Haas
     
  18. anonymous

    anonymous Guest

    Yes sir
     
  19. anonymous

    anonymous Guest

    TRUMPS WINNING !!!!!!!!!!!
     
  20. anonymous

    anonymous Guest

    Make Rickys little guy yuge again!